PDCD1 and Merkel cell skin cancer: In this sense, an increasing body of evidence on the role of the immune system in MCC control has paved the way for the use of checkpoint inhibitors, namely anti-PD-1 (programmed cell death 1) and anti-PD-L1 (programmed cell death protein ligand 1) [13].